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Introduction: Acetylcholinesterase inhibitors (AChEIs) are commonly used to treat
mild to moderate cases of Alzheimer disease (AD). To the best of our knowledge, there
has been no study estimating the risk of bleeding and cardiovascular events in patients
with non-hypertensive AD. Therefore, this study aimed to estimate the association
betweenAChEIs and the riskof bleedingandcardiovascular ischemicevents inpatients
with non-hypertensive AD.
Methods: A nested case-control study was conducted to estimate the risk of bleeding
and ischemic events (angina, myocardial infarction [MI], and stroke) in patients with
AD. This study was conducted using the UK Clinical Practice Research Datalink and
Hospital Episode Statistics (HES) databases. The study cohort consisted of ADpatients
≥65 years of age. The case groups included all AD subjects in the database who had
a bleeding or ischemic event during the cohort follow-up. Four controls were selected
for each case. Patients were classified as current users or past users based on a 60-day
threshold of consuming the drug. Simple and multivariable conditional logistic regres-
sion analyses were used to calculate the adjusted odds ratio for bleeding events and
cardiovascular events.
Results: We identified 507 cases and selected 2028 controls for the bleeding event
cohort and 555 cases and 2220 controls for the ischemic event cohort. The adjusted
odds ratio (OR) (95%confidence interval [CI]) for the associationofAChEI usewas0.93
(0.75 to 1.16) for bleeding events, 2.58 (1.01 to 6.59) for angina, and 1.89 (1.07 to 3.33)
forMI. Past users of AChEIs were also at increased risk of stroke (1.51 [1.00 to 2.27]).
Discussion: This is the first study assessing the risk of bleeding and cardiovascular
events in patients with non-hypertensive AD. Our findings could be of great interest
for clinicians and researchers working on AD.
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1 INTRODUCTION
Cardiovascular disease (CVD) is oneof the leading causesof death, con-
tributing to ≈30% of mortality worldwide.1 There are several known
modifiable risk factors for CVD, including smoking, increased plasma
low-density lipoprotein cholesterol (LDL-C), sedentary lifestyle,2 phys-
ical inactivity, and arterial hypertension.3
Patients living with hypertension are at greater risk for bleeding
events, angina, and myocardial infarction (MI).4 On the other hand,
non-hypertensive patients are less exposed to acute ischemic events,
including stroke, MI, and angina. The risk of stroke has been found to
be significantly higher in hypertensive compared to non-hypertensive
individuals (adjusted odds ratio [OR] 2.98, 99% confidence interval [CI]
2.72 to 3.28).5 Non-hypertensive individuals also have a lower risk of
overall cardiovascular diseases (including MI and angina) 46.1% (95%
CI 45.5 to 46.8) compared to hypertensive patients 63.3% (95% CI
62.9 to 63.8).6 Furthermore, it has been suggested that hypertension
may reduce the risk of Alzheimer’s disease (AD) in patients 60 years
of age or older7 and that individuals with controlled hypertension may
be prescribed medications that act similarly to acetylcholinesterase
inhibitors (AChEIs); by enhancing cholinergic activity one’s risk of CVD
could be reduced.8
Alzheimer’s disease (AD) is the most common type of dementia
affecting elderly people. It is characterized by the neurodegeneration
of the central nervous system (CNS). It can also be considered as a dis-
ease with an essential vascular component. Current evidence empha-
sizes the role of CVDas a commonpathophysiological base for the con-
nection between the CNS and cardiovascular system.9 Elderly patients
with CVD are known to be at higher risk for AD, and the co-existence
of both diseases increases patient suffering and treatment expenses.9
CVDs can cause dementia through cerebral hypoperfusion, emboli,
infarction, or hypoxia.10 Mixed dementia can result from the combi-
nation of both cerebrovascular disease and neurodegeneration, and
accounts for the majority of cases among the elderly.11 Considering
the evidence presented, there is a tangible and multifaceted associa-
tion between cardiovascular health and neurological health.
AChEIs are a group of drugs commonly used to treat mild to moder-
ate cases of AD. They stimulate muscarinic cholinergic pathways and
thereby could potentially reduce the risk of CVD.12 As such, AChEIs
would counteract the effects of sympathetic activation and thus may
reduce blood pressure and platelet aggregation. Platelets, in particu-
lar, represent a potential link between vascular inflammation and AD.
In AD patients, platelets contribute to amyloid beta (Aβ) accumula-
tion in the CNS.13 Furthermore, patients with coronary artery dis-
ease and dementia have shown higher platelet activation compared to
thosewithoutdementia. As such, platelet activationmaybridge thegap
betweenCVDand dementia, andmay be considered as an indicator for
the severity of dementia and a potential new treatment target in AD
patients.14
In light of the evidence presented, treating individuals living with
AD with AChEIs may thus increase the risk of bleeding events due to
the potential inhibition of platelet aggregation. AChEIs have been sug-
gested to increase the risk of gastrointestinal (GI) bleeding in patients
Research in Context
1. SystematicReview:PatientswithAlzheimer’s disease and
hypertension are more prone to cardiovascular disease
(CVD). Previous literature has shown that the use of
acetylcholinesterase inhibitors (AChEIs) in AD reduced
the risk of such events. However, there is no study assess
the risk of bleeding and ischemic events in patients with
non-hypertensive AD. This is the first study to assess the
risk of bleeding and ischemic events in patients with non-
hypertensive ADwho are taking AChEIs.
2. Interpretation:Our results showed that theuseofAChEIs
may not affect the risk of bleeding; however, AChEIswere
associated with an increased risk of angina and myocar-
dial infarction (MI) in patients with non-hypertensive AD.
The present study controlled for hypertension, which
plays a significant role in cardiovascular health and bleed-
ing.
3. FutureDirections: This study had small sample size. Large
studies with bigger sample sizes are required to further
confirm these findings.
with peptic ulcers; however, there is limited evidence on the risk of
overall bleeding events, intracranial bleeding, and stroke.15
The studies mentioned above suggest that there is a close relation-
ship between one’s cardiovascular health and the risk of AD. As such,
the aimof the present study is to determinewhether there is a relation-
ship between AChEIs and cardiovascular events in non-hypertensive
patients. We hypothesize that the use of AChEIs increases the risk of
bleeding while reducing the risk of ischemic events (MI, stroke, and
angina) in patients with non-hypertensive AD.
2 METHODS
2.1 Study type
A nested case-control study.
2.2 Ethical approval
The studywas approvedby the Scientific andEthical AdvisoryCommit-
tee of theClinical Practice ResearchDatabase (CPRD, no. 17_172), and
the ethics reviewboard of theMcGill UniversityHealthCentre. Patient
consent was not required.
2.3 Source of data
Weused the data from the Clinical Practice ResearchDatabase (CPRD
and Hospital Episode Statistics (HES) database. The CPRD is a large
computerized database of longitudinal records from primary care
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institutions.16 The age and sex distribution of patients in the CPRD
has been shown to be representative of the UK population.17 Prescrip-
tions are recorded using a coded drug dictionary based on the UK Pre-
scription Pricing Authority Dictionary. Only data that pass quality con-
trol and are considered “up-to-standard” are included in the CPRD
database. The CPRD database has a high level of completeness, and
has been validated for epidemiological data on patients with bleed-
ing events,18 CVD,19 and AD.20 The recorded information on drug
exposure and diagnoses has been validated and shown to be of high
quality.16
2.4 Source population
We identified patients 65 years of age or older with a first-time diag-
nosis of AD according to the International Classification of Diseases,
Tenth Revision (ICD-10) coding systems, which were recorded in the
computerized database between January 1998 and December 2013.
We also identified patients who received a first-time prescription of
AChEIs during the same period. We selected 1998 as the beginning of
the study period point, as it represents 2 years after the beginning of
the commercialization of AChEIs in the UK. An algorithm described by
Imfeld et al.21 was used to identify patients with well-defined AD. The
AD patients had to satisfy at least one of the following criteria: (1) a
diagnosis of AD followedby at least one prescription for anAD-specific
medication, or vice versa; (2) two prescriptions for anAD-specificmed-
ication; (3) at least two recordings of an AD diagnosis; (4) an AD diag-
nosis after a specific dementia test, or (5) an AD diagnosis preceded
or followed by any registered dementia symptoms.22 All participants
should have at least two consecutive years of up-to-standard follow-
up in the CPRD records before the diagnosis of AD. The cohort was fol-
lowed until the development of one of the study outcomes (bleeding or
ischemic events), end of the study (December 31, 2013), or end of reg-
istration with the general practice, whichever happened first.
Patients with clotting or bleeding disorders (ie, hemophilia, throm-
bocytopenia purpura [TP], and vonWillebrand disease) were excluded.
Patients diagnosed with conditions that could affect cardiovascular
health (ie., Pagett’s disease, osteoporosis, osteomalacia,23 cancer,23
HIV,24 congestive heart failure, rheumatoid arthritis,25 peripheral
vascular disease, and alcoholism)26 as well as patients who used
medications known to affect the risk of CVD27 (ie., corticosteroids,
anti-epileptic drugs, anxiolytics, calcium-vitamin D supplements, β-
blockers, antihypertensive drugs, and bisphosphonates) prior to the
diagnosis of ADwere also excluded.
2.4.1 Study series
For our nested case-control study, we used the methodology that has
already been published by our research group.28 We explain the study
groups below.
2.4.2 Case series
The case series included all AD subjects registered in the databasewho
had a bleeding event (first case group) or ischemic event (second case
group) during the cohort follow-up. All cases should be recorded at
least 1 year after the diagnosis of AD (to ensure a sufficient period of
exposure to AChEIs) between 1998 and 2013. All cases were required
to have no history of bleeding or ischemic events at the time of diag-
nosis of AD. The date of the diagnosis of a cardiovascular or bleeding
event was served as the index date for all cases.
Bleeding was defined based on a comprehensive list of bleeding
codes (96 International Classification of Diseases [ICD]-10) and was
categorized into intracranial, extracranial bleeding, and GI bleeds.
Ischemic events were categorized as stroke, MI, or angina. Angina was
categorized as stable and unstable. If a patient had more than one
ischemic event, the former was only considered in the analysis.
2.4.3 Control series
Four matched controls were selected per case by using incidence-
density sampling.29 For each case, the controlswere randomly sampled
from the set (ie., “risk set”) of AD subjects that are alive and outcome-
free on the index date of the matching case. Controls were matched to
the cases by age (±2 years), sex, up-to-standard follow-up in the CPRD
(±1 year), calendar time (same index date as for cases), and duration of
AD (±6months). The same inclusion/exclusion criteriawas also applied
to controls.
2.5 Exposure assessment
We ascertained the use of AChEIs (ie., donepezil, oral rivastigmine,
transdermal rivastigmine, and galantamine) for all cases and controls
between the cohort entry and the index date. Patients were classified
as current users if the last prescription of AChEIs was within 60 days
prior to the index date and past users if it was > 60 days. Patients with
no prescription of AChEIs between the cohort entry and index date
were considered as non-users. We derived a quantitative measure of
theuseofAChEIs by calculating thenumberof days coveredby thepre-
scriptions during the year prior to the index date and the Proportion of
Days Covered (PDC).30 PDC adherence were classified into three cat-
egories (low<0.20, moderate 0.20≤PDC<0.80, and high≥0.80).
2.6 Statistical analysis
Previous studies showed that 32% of AD patients had brain bleeds.31
Based on this information and 95% significant level with an alpha error
of 0.05, this study required a minimum sample size of 325 cases and
1300 controls.
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F IGURE 1 Flow chart of cases and controls
We performed simple and multivariable conditional logistic regres-
sionanalyses to calculate crudeandadjustedodds ratios (ORs) estimat-
ing rate-ratios (RRs), and the corresponding 95% confidence intervals
(CIs). In the multivariable models, the adjusted ORs for stroke, unsta-
ble angina, MI, and bleeding events were estimated by adjusting for
the following potential confounders: age, body mass index (BMI; <20,
20-24, 25-29, >30 kg/m2, and unknown), smoking status (none, cur-
rent, ex-smokers, unknown), lengthof stay at hospital, poormobility (ie,
home visits by a general practitioner [GP], or use of walking aid), insti-
tutionalization (ie, patient receiving residential care, in a care home, or
nursing care), medical conditions increasing the risk of cerebrovascu-
lar accident, the use of anticoagulant or ant-platelets drugs (heparin
group, platelet aggregation inhibitors excl. heparin, vitamin K antag-
onists, direct thrombin inhibitors, or direct factor Xa inhibitors), and
the use of selective serotonin reuptake inhibitors (SSRIs). All statisti-
cal analyses were carried out using SAS version 9.3 (SAS Institute Inc,
Cary, NC, USA).
3 RESULTS
A total of 10,459 AD patients who fulfilled the source-cohort criteria
were included in the cohort population. Therewere 507 cases of bleed-
ing events identified over the follow-up, and accordingly, 2028 controls
were selected. Their ages ranged from 65 to ≥85 years. A total of 260
cases were AChEIs users and 247 cases were non-users. Within the
control group, 1030 patients were users of AChEIs and 998 patients
were non-users (Figure 1).
3.1 Bleeding risk
There was no association between AChEI use and bleeding events
(adjusted OR = 0.93, 95% CI= 0.75 to 1.16). There was no risk associ-
ation with either current or past AChEI use. When we assessed adher-
ence to AChEIs, the adjusted OR (95% CI) was 0.91 (0.57 to 1.47) for
PDC<0.2, 0.97 (0.70 to 1.34) for PDC0.2 to 0.8, and 0.92 (0.72 to 1.18)
for PDC ≥0.80. There was no risk association concerning the adher-
ence to treatment among current and past users, as well as non-users.
A sub-population of intracranial bleeding risk showed no risk associ-
ation between AChEI users and non-users (adjusted OR = 1.03, 95%
CI=0.75 to 1. 16,P= .86). Overall, the results indicate that these drugs
may not be associated with the risk of bleeding events (Tables 1 and 2,
Tables S1 and S2).
3.2 Ischemic events
3.2.1 Angina
A total of 53 cases and 212 controls were selected. Among them, 30
angina cases were AChEI users and 23 cases were non-users. For the
controls, 100 patients were AChEI users and 112 patients were non-
users. Cases were more regularly taking anticoagulants and statins,
consistent with their CVD presentation. The use of AChEIs was asso-
ciated with a higher rate of angina (adjusted OR= 2.58, 95% CI= 1.01
to 6.59,). No risk association was found with current usage of AChEI.
A high risk was associated with past usage (adjusted OR = 12.22, 95%
CI= 2.09 to 71.51).
A high risk was associated with a PDC <0.2 (adjusted OR = 8.29,
95% CI = 1.84 to 37.30) in all users. A high risk of angina risk was also
found specifically in current users of AChEIswith a PDC<0.2 (adjusted
OR = 7.05, 95% CI = 1.33 to 37.50). However, no risk association was
found for a PDC between 0.2 and 0.8 and PDC ≥0.8 (Table 3 and Table
S3).
3.2.2 Myocardial infarction
Ninety cases of MI and 360 controls were selected. A total of 55 MI
cases were AChEI users and 35 cases were non-users. For the con-
trol patients, 174 patients were AChEI users and 186 patients were
non-users. Any use of AChEIs was associated with a higher rate of
MI (adjusted OR = 1.89, 95% CI = 1.07 to 3.33). Current users had
a higher rate of MI (adjusted OR = 2.07, 95% CI = 1.15 to 3.73). A
high risk of MI was found in all users with a PDC between 0.2 and
0.8 (adjusted OR = 2.69, 95% CI = 1.17 to 6.17). A higher rate of MI
was also found in current users of AChEIs with a PDC between 0.2
and 0.8 (adjusted OR = 3.74, 95% CI = 1.36 to 10.30,). PDC <0.2 and
PDC ≥0.8 were not associated with an increased risk of MI (Table 4,
Table S4).
3.2.3 Stroke
Four hundred twelve cases of stroke and 1648 controls were assessed.
Among them, 225 stroke cases were AChEI users and 187 cases
were non-users. Within the control group, 785 patients were AChEI
users and 864 patients were non-users. Past users of AChEIs were
at increased risk of stroke (adjusted OR = 1.51, 95% CI = 1.00 to
2.27), whereas current users were not. A high risk was found in only
past users with a PDC between 0.2 and 0.8 (adjusted OR = 1.97, 95%
CI= 1.13 to 3.41) (Table 5 and Table S5).
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TABLE 1 Crude and adjusted estimates of the odds ratio for the association of adherence with prescribed acetylcholinesterase inhibitors in
the year prior to index date with bleeding risk (vs non-use)
No. %
Exposure Cases (n= 507) Controls (n= 2028) Crude odds ratio (95%CI) Adjusted odds ratio (95%CI)†
AChEI use
No use 51.28 50.79
Any use 48.72 49.21 0.98 (0.80-1.20) 0.93 (0.75-1.16)
PDC<0.2 5.52 5.82 0.94 (0.60-1.47) 0.91 (0.57-1.47)
0.2≤ PDC<0.8 13.41 13.17 1.01 (0.74-1.38) 0.97 (0.70-1.34)
PDC≥0.8 29.78 30.23 0.97 (0.77-1.23) 0.92 (0.72-1.18)
Current 39.64 40.68 0.96 (0.78-1.19) 0.93 (0.74-1.17)
PDC<0.2 2.76 3.30 0.80 (0.42-1.52) 0.85 (0.43-1.65)
0.2≤ PDC< 0.8 8.68 8.88 0.97 (0.67-1.40) 0.98 (0.67-1.44)
PDC≥0.8 28.21 28.50 0.98 (0.77-1.25) 0.92 (0.72-1.19)
Past use 9.07 8.53 1.05 (0.74-1.51) 0.95 (0.65-1.38)
PDC<0.2 2.76 2.51 1.09 (0.60-2.00) 0.99 (0.52-1.88)
0.2≤ PDC< 0.8 4.73 4.29 1.10 (0.68-1.77) 0.96 (0.58-1.59)
PDC≥0.8 1.58 1.73 0.91 (0.42,1.98) 0.86 (0.38-1.93)
TABLE 2 Use of acetylcholine inhibitors and intracranial bleeding risk (vs non-use)
No. %
Exposure Cases (n= 208) Controls (n= 832) Crude odds ratio (95%CI) Adjusted odds ratio (95%CI)†
AChEI use
No use 48.08 52.40 1 Ref
Any use 51.92 47.60 1.20 (0.88-1.63) 1.03 (0.73-1.45)
Current 41.35 39.54 1.15 (0.83-1.59) 1.02 (0.71-1.45)
Past use 10.58 8.05 1.44 (0.85-2.44) 1.09 (0.62-1.93)
TABLE 3 Crude and adjusted odds ratio for the association of adherence with prescribed acetyl cholinesterase inhibitors in the year prior to
index date with angina (vs non-use)
No. %
Exposure Cases (n= 53) Controls (n= 212) Crude odds ratio (95%CI) Adjusted odds ratio (95%CI)†
AChEI use
No use 43.40 52.83
Any use 56.60 47.17 1.52 (0.80-2.89) 2.58 (1.01-6.59)
PDC<0.2 13.21 8.49 1.97 (0.72-5.41) 8.29 (1.84-37.30)
0.2≤ PDC< 0.8 11.32 8.96 1.61 (0.57-4.55) 2.84 (0.65-12.35)
PDC≥0.8 32.1 27.9 1.34 (0.62-2.88) 1.49 (0.48-4.62)
Current 47.19 41.51 1.44 (0.74-2.81) 2.11 (0.79-2.66)
PDC<0.2 9.43 5.19 2.30 (0.68-7.77) 7.05 (1.33-37.50)
0.2≤ PDC< 0.8 7.55 6.60 1.43 (0.43-4.78) 1.67 (0.30-9.48)
PDC≥0.8 30.19 29.72 1.26 (0.57-2.74) 1.29 (0.39-4.34)
Past use 9.43 5.66 2.12 (0.66-6.81) 12.22 (2.09,71.51)
PDC<0.2 3.77 3.30 1.42 (0.28-7.20) 9.82 (0.96-100.21)
0.2≤ PDC< 0.8 3.77 2.36 1.94 (0.33-11.33) 7.32 (0.52-103.97)
PDC≥0.8 1.89 0.00 ———————- —————–
6 of 9 AL-HAMED ET AL.
TABLE 4 Crude and adjusted odds ratio for the association of adherence with prescribed acetyl cholinesterase inhibitors in the year prior to
index date withMI (vs nonuse)
No. %
Exposure Cases (n= 90) Controls (n= 360) Crude odds ratio (95%CI) Adjusted odds ratio (95%CI)†
AChEI use
No use 38.89 51.67
Any use 61.11 48.33 1.69 (1.05-2.72) 1.89 (1.07-3.33)
PDC<0.2 5.56 5.83 1.19 (0.41-3.47) 1.26 (0.38-4.19)
0.2≤ PDC< 0.8 18.89 12.22 2.25 (1.08-4.67 2.69 (1.17-6.17)
PDC≥0.8 36.67 30.218 1.63 (0.94-2.82) 1.73 (0.91-3.30)
Current 55.56 40.00 1.86 (1.14-3.04) 2.07 (1.15-3.73)
PDC<0.2 3.33 3.33 1.24 (0.30-5.13) 1.49 (0.32-7.04)
0.2≤ PDC< 0.8 15.56 8.61 3.01 (1.26-7.18) 3.74 (1.36-10.3)
PDC≥0.8 36.67 2.06 1.71 (0.99-2.96) 1.81 (0.95-3.47)
Past use 5.56 8.33 0.91 (0.33-2.47) 1.08 (0.34,3.39)
PDC<0.2 2.22 2.50 1.22 (0.26-5.82) 1.14 (0.17.7.52)
0.2≤ PDC< 0.8 3.33 3.61 1.23 (0.33-4.63) 1.46 (0.34-6.19)
PDC≥0.8 0.0 2.22 0.00————— 0.0————–
TABLE 5 Crude and adjusted odds ratio for the association of adherence with prescribed acetyl cholinesterase inhibitors in the year prior to
index date with Stroke (vs nonuse)
No. %
Exposure Cases (n= 412) Controls (n= 1648) Crude odds ratio (95%CI) Adjusted odds ratio (95%CI)†
AChEI use
No use 45.39 52.37
Any use 54.61 47.63 1.33 (1.07-1.66) 1.22 (0.97-1.54)
PDC<0.2 5.58 6.13 1.04 (0.63-1.72) 1.00 (0.59-1.68)
0.2≤ PDC< 0.8 15.53 13.11 1.36 (0.98-1.89) 1.23 (0.87-1.73)
PDC≥0.8 33.50 30.218 1.38 (1.07-1.79) 1.26 (0.96-1.65)
Current 44.42 28.40 1.29 (1.02-1.62) 1.17 (0.91-1.49)
PDC<0.2 3.16 3.70 0.93 (0.48-1.80) 0.89 (0.45-1.77)
0.2≤ PDC< 0.8 9.95 9.77 1.14 (0.77-1.68) 1.00 (0.67-1.50)
PDC≥0.8 31.31 26.64 1.40 (1.08-1.83) 1.28 (0.97-1.70)
Past use 10.19 7.52 1.59 (1.08-2.36) 1.51 (1.00-2.27)
PDC<0.2 2.43 2.43 1.17 (0.57-2.40) 1.10 (0.52.2.32)
0.2≤ PDC< 0.8 5.58 3.34 2.03 (1.20-3.43) 1.97 (1.13-3.41)
PDC≥0.8 2.18 1.76 1.45 (0.67-3.12) 1.33 (0.60-2.95)
4 DISCUSSION
The findings of our study showed no association between AChEI use
andbleeding in patientswith non-hypertensiveAD. These results are in
accordancewith the cohort-study conductedbyThavornet al., inwhich
they found no association between the use of AChEIs and upper GI
bleeding in an elderly population.15 In addition, this was in agreement
with our in vivo study, in which we showed that the AChEI, donepezil,
did not affect hemostasis and platelet function.32 Thus AChEI use does
not appear to be associated with increased bleeding risk.
This study also showed that AChEI users were at increased risk
of ischemic events (MI, angina, and stroke) in patients with non-
hypertensive AD. Past use of AChEIs was associated with angina and
stroke, whereas, current use was associatedwithMI and angina. These
differences could be attributed to the adverse effects of these drugs,
or occur simply because the patient was not adherent to their medi-
cations. These findings contradict those reported by Nordstrom et al.,
who found a reduced risk of MI among AChEI users.33 A study con-
ducted by Pariente et al., observed an increased risk in MI in patients
concomitantly consuming AChEIs and anti-psychotics.34 Our study did
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not control for the consumption of anti-psychotics; therefore a drug
interaction remains a possibility. It has been shown that anti-psychotics
increase the risk of cardiometabolic disturbances, probably by increas-
ing levels of triglycerides and low-density lipoprotein (LDL).35
Furthermore, the results of this studydemonstrate an increased risk
in stroke in past users only without a change in risk in current users.
These results are not in accordance with those found by Lin et al., in
which they found a reduced risk of stroke among AChEI users com-
pared to non-users.36 The studies mentioned above did not control
for physical activity, or BMI, thus drawing different conclusions on MI
and stroke risk. BMI is an independent predictor of CVD seeing as it is
a measure of obesity, and thus metabolic syndrome, ultimately influ-
encing the results of the studies mentioned above.37 Lifelong phys-
ical activity is a strong predictor of cardiovascular health, and thus
could have contributed to differences between studies.38 The studies
byNordstromet al. andTan et al. used a Swedish database to obtain the
results for their analyses. The Sweden population was among themost
physically active in all of Europe (87.2%).39 Drawing a comparison to
theUK, fromwhich our source populationwas extracted, 75.8% is ade-
quately active.39 Our study also controlled for confounding variables
for CVD such as hypertension and smoking, which were not controlled
for in the studies mentioned above.
The results from this study reveal that patient adherence to AChEIs
is an important contributor to the risk of cardiovascular events. Com-
pliance with medication remains a problem in patients living with AD.
According to the literature, one of the main reasons for not adhering
to the treatment regimen is the perception of a lack of benefits and
forgetfulness.40 This will effectively result in the worsening of cog-
nitive function and may have a deleterious effect on cardiovascular
health.41 Based on the results of the study, although one can infer that
a lack of adherence to AChEIsmay be associatedwith an increased risk
of cardiovascular events, the evidence remains limited. Nevertheless, a
possible mechanism of this association can be extracted fromUmegaki
et al., in which they discovered that acute administration of donepezil
was associated with an increase in sympathetic nervous system acti-
vation, whereas long-term consumption attenuates sympathetic activ-
ity allowing the parasympathetic system to predominate.42 To further
corroborate these findings, it is important to acknowledge that a lack
of drug adherencemay also be a signal for poor adherence to a healthy
lifestyle, further impacting cardiovascular health.
Our findings contradicted our initial hypothesis, whichwas based on
the mechanism by which sympathetic hyperactivity increased platelet
activation. This would imply that by increasing the concentration
of acetylcholine, through the use of AChEIs, the sympathetic ner-
vous system would be attenuated, thereby reducing platelet activa-
tion. Ozdemir et al. demonstrated that there was an enhanced mean
platelet volume with sympathetic over-activity, demonstrating the
presence of platelet activation.43 Furthermore, Bennett et al. revealed
that carbachol, an analog of acetylcholine, inhibits platelet activation
through the attenuation of thrombin receptor.44 In addition, AChEIs
have been reported as having an anti-platelet effect in the endothe-
lial cells, which play an essential role in ischemic stroke development.36
These differences could be due to a different population being
studied, seeing as we placed an emphasis on non-hypertensive AD
patients.
4.1 Strengths and limitations
Our studywas the first to determine the risk of bleeding and cardiovas-
cular events in non-hypertensive AD patients. The present study con-
trolled for hypertension, which has a significant role in cardiovascular
health and bleeding. Another strength of this study was the ability to
stratify the results based on patient adherence.
Limitations potentially affecting the findings of the present study
are associated with the risk of selection bias among both cases and
controls. Measures were put in place to reduce the risk of selection
bias by stratifying the variables that could have ultimately affected
the outcomes measured. The variables included are age, BMI, smoking
status, hospitalization duration, morbidity, institutionalization, medi-
cal conditions, and medications known to affect bleeding or cardio-
vascular health.45 In addition, this study used information extracted
from the Clinical Practice ResearchDatabase (or CPRD), a high-quality
population-based database. It contains a diverse population of par-
ticipants and their associated outcomes and exposures, which helped
reduce likelihood of selection bias.16 In addition, four controls were
matched per selected case using incidence-density sampling, which is
considered one of the most effective ways to reduce bias in select-
ing a control group sample.29 Furthermore, this study strictly included
well-defined AD patients, following a validated algorithm conducted
by Imfeld et al.46 Another limitation is that the sample size of this
case-control study was limited by our restrictive inclusion criteria that
aimed to minimize the risk of selection bias. Therefore, future stud-
ies with larger sample sizes are ideal in order to corroborate our find-
ings. Another limitation is the drug tolerance that may develop when
patients are consuming highly reversible drugs such as donepezil and
galantamine, but this may not be the case with slowly reversible drugs
such as rivastigmine. As such, if patients consume these drugs consis-
tently, their effectsmay quickly diminish, and the dosewould therefore
need to be adjusted.
5 CONCLUSION
The use of AChEIs may be associated with a modest increase in the
risk ofMI and angina in patientswith non-hypertensive AD; however, it
does not affect the risk of bleeding events. Future large-sampled well-
controlled studies are required to confirm these findings.
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